https://www.resverlogix.com/investors/news.html?article=720
I don't see mention (update) of the, scheduled early August Type C Meeting with FDA for CORAL Phase 3 High-rick COVID-19 Outpatient Study Design in the article?
COVID-19:
"Studies – published in prestigious scientific journals (including Cell) – demonstrate that apabetalone has the potential to act against COVID-19 with a unique dual-mechanism: first by preventing viruses from entering the cells and replicating; and second by averting excessive inflammatory reactions that can cause severe and lasting organ damage. The investigational treatment could potentially reduce the severity and duration of COVID-19. Apabetalone’s unique dual-mechanism also means that it has the potential to show efficacy against new COVID-19 variants and may even help fight other viruses.
Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for COVID-19 in Canada and the United States. EVERSANA™ is currently leading clinical outreach and advocacy for apabetalone in the Canadian market. "
Saying one thing to deflect attention from another ... perhaps!
We're well past early August!
Koo
